Cross-sectional analysis shows perivascular space alterations precede dementia in mutation carriers, indicating potential early biomarkers.
INTRODUCTION Perivascular space (PVS) alterations are traditionally linked to cardiovascular risk factors and aging, but may also play a direct role in Alzheimer's disease (AD). To reduce confounding from age‐related comorbidities, we examined PVSs in autosomal dominant AD (ADAD). METHODS In this cross‐sectional study of 96 non‐demented individuals (62 mutation carriers), we quantified PVS count fraction and mean diameter in white matter and basal ganglia using automated magnetic resonance imaging analysis. Linear mixed models assessed group differences along the disease course, adjusting for cardiovascular risk factors. RESULTS Compared to non‐carriers, mutation carriers showed lower PVS count fraction in white matter and basal ganglia, and larger PVS diameter in basal ganglia and the temporal lobe. Changes were evident up to 18 years before expected dementia onset and followed trajectories similar to amyloid beta 42 and tau biomarkers. DISCUSSION ADAD is associated with early PVS alterations, suggesting perivascular changes may be integral to primary AD pathology. Highlights Autosomal dominant Alzheimer's disease (ADAD) mutation carriers have reduced magnetic resonance imaging–visible perivascular space (PVS) count fraction in the white matter and basal ganglia. ADAD mutation carriers show enlarged PVS in the basal ganglia and temporal white matter. PVS alterations start 18 years before the estimated time of dementia diagnosis. The spatial localization of PVS changes overlaps with regions of amyloid beta (Aβ) accumulation. The temporal evolution of PVS alterations aligns with Aβ and tau changes in the cerebrospinal fluid.
No takes yet. Share an insight, caveat, or question.
Leone et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: